REZOLUTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
REZOLUTE, INC. (RZLT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 346.75 thousand shares for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-09-24
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 7.61K shares, a 71.46% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 334.43K shares, a 33343.40% increase year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 3.20K shares.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 1.50K shares.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2026 was 346.75K shares, a 397.72% increase from fiscal 2025.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 69.67K shares, a 37.27% decline from fiscal 2024.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 111.06K shares, a 4.26% decline from fiscal 2023.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 116.00K shares, a 48.72% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 7.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | 342.05K shares derived: sum of 2 quarters · filed 2026-09-24 | 345.25K shares derived: sum of 3 quarters · filed 2026-09-24 | 346.75K shares 10-K · filed 2026-09-24 | |
| 2026-03-31 | 334.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | 337.63K shares derived: sum of 2 quarters · filed 2026-05-12 | 339.13K shares 10-Q · filed 2026-05-12 | 365.80K shares derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-12-31 | 3.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | 4.70K shares 10-Q · filed 2026-02-12 | 31.37K shares derived: sum of 3 quarters · filed 2026-09-24 | 32.37K shares derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-09-30 | 1.50K shares 10-Q · filed 2025-11-06 | 28.17K shares derived: sum of 2 quarters · filed 2026-09-24 | 29.17K shares derived: sum of 3 quarters · filed 2026-09-24 | ||
| 2025-06-30 | 26.67K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | 27.67K shares derived: sum of 2 quarters · filed 2026-09-24 | 69.67K shares 10-K · filed 2026-09-24 | ||
| 2025-03-31 | 1.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | 43.00K shares 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 42.00K shares 10-Q · filed 2025-02-12 | ||||
| 2024-06-30 | 68.06K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-17 | 69.06K shares derived: sum of 2 quarters · filed 2025-09-17 | 84.06K shares derived: sum of 3 quarters · filed 2025-09-17 | 111.06K shares 10-K · filed 2025-09-17 | 110.00K shares 10-K · filed 2024-09-19 |
| 2024-03-31 | 1.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | 16.00K shares derived: sum of 2 quarters · filed 2024-05-15 | 43.00K shares 10-Q · filed 2024-05-15 | 43.00K shares derived: sum of 4 quarters · filed 2024-09-19 | |
| 2023-12-31 | 15.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | 42.00K shares 10-Q · filed 2024-02-13 | 42.00K shares derived: sum of 3 quarters · filed 2024-09-19 | ||
| 2023-09-30 | 27.00K shares 10-Q · filed 2023-11-13 | 27.00K shares derived: sum of 2 quarters · filed 2024-09-19 | |||
| 2023-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-19 | 116.00K shares 10-K · filed 2024-09-19 | |||
| 2023-03-31 | 116.00K shares 10-Q · filed 2023-05-11 | ||||
| 2022-06-30 | 17.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-14 | 78.00K shares 10-K · filed 2023-09-14 | |||
| 2022-03-31 | 61.00K shares 10-Q · filed 2022-05-12 | ||||
| 2021-06-30 | 391.00K shares 10-K · filed 2022-09-15 | ||||
| 2018-06-30 | -249.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-10 | 250.00 shares 10-K · filed 2019-09-10 | 250.00K shares 10-K · filed 2018-10-15 | ||
| 2018-03-31 | 250.00K shares 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |